


Iptacopan

Cat. No.:	HY-127105		
CAS No.:	1644670-37-0		
Molecular Formula:	C ₂₅ H ₃₀ N ₂ O ₄		
Molecular Weight:	422.52		
Target:	Complement System		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (118.34 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3668 mL	11.8338 mL	23.6675 mL
		5 mM	0.4734 mL	2.3668 mL	4.7335 mL
10 mM		0.2367 mL	1.1834 mL	2.3668 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (11.83 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5 mg/mL (11.83 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (11.83 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC ₅₀ value of 10 nM. Iptacopan shows direct, reversible, and high-affinity binding to human factor B with a K _D of 7.9 nM. Iptacopan targets the underlying cause of complement 3 glomerulopathy (C3G) ^{[1][2]} .
IC ₅₀ & Target	KD: 7.9 nM (factor B) ^[2] IC50: 10 nM (factor B) ^[2]

In Vitro	<p>Iptacopan (LNP023) demonstrates potent inhibition of alternative complement pathway (AP)-induced membrane attack complex (MAC) formation in 50% human serum (IC₅₀ value of 130 nM)^[2].</p> <p>?Iptacopan (LNP023) exhibits excellent selectivity over other proteases affording IC₅₀ values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM)^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Iptacopan (LNP023; 20-180 mg/kg; oral administration) prevents KRN (150 μL)-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats^[2].</p> <p>?LNP023 exhibits moderate half-lives (T_{1/2}; Wistar Han rats 3.4 h, beagle dogs 5.5 h) and C_{max} (Wistar Han rats 410 nM, beagle dogs 2200 nM) following oral administration (rat 30 and, dog 10 mg/kg)^[3].</p> <p>?Iptacopan exhibits terminal elimination half-lives (T_{1/2}; Wistar Han rats 7 h, beagle dogs 5.6 h) due to high plasma clearance (8, and 2 mL/min/kg respectively combined with large volumes of distribution (2.3, and 0.6 L/kg respectively) following intravenous administration (rat 1.0 and, dog 0.1 mg/kg)^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="347 625 1515 863"> <tr> <td>Animal Model:</td> <td>C57BL/6 mice with KRN-induced arthritis^[2]</td> </tr> <tr> <td>Dosage:</td> <td>20, 60, and 180 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally gavaged; twice a day (b.i.d.) for 14 days</td> </tr> <tr> <td>Result:</td> <td>Blocked KRN-induced arthritis.</td> </tr> </table>	Animal Model:	C57BL/6 mice with KRN-induced arthritis ^[2]	Dosage:	20, 60, and 180 mg/kg	Administration:	Orally gavaged; twice a day (b.i.d.) for 14 days	Result:	Blocked KRN-induced arthritis.
Animal Model:	C57BL/6 mice with KRN-induced arthritis ^[2]								
Dosage:	20, 60, and 180 mg/kg								
Administration:	Orally gavaged; twice a day (b.i.d.) for 14 days								
Result:	Blocked KRN-induced arthritis.								

CUSTOMER VALIDATION

- Cell Stem Cell. 2023 Oct 5;30(10):1315-1330.e10.
- Biomed Pharmacother. September 2022, 113433.
- Biomed Chromatogr. 2021 Mar;35(3):e5006.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Dimitrios C Mastellos, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul;55(3):167-175.
- [2]. Anna Schubart, et al. Small-molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931.
- [3]. Nello Mainolfi, et al. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA